Regional citrate anticoagulation for single-needle hemodialysis: a prospective clinical study

Blood Purif. 2007;25(5-6):454-6. doi: 10.1159/000111808. Epub 2007 Nov 29.

Abstract

Aim: Regional citrate anticoagulation protocol for single-needle hemodialysis was tested prospectively for safety and efficacy.

Methods: 15 chronic dialysis patients at risk of bleeding were included. 4% trisodium citrate (200 ml/h), calcium-free dialysate and 1 mol/l calcium chloride (7 ml/h) were used. After dialysis the antithrombotic effect in the circuit was assessed visually (grade 5, no clotting, to 1, total occlusion) and serum citrate was measured.

Results: Of 32 dialyses performed, 94% were uneventful and in 2 cases (6%) there was severe (ionized calcium < or = 0.8 mmol/l) but asymptomatic hypocalcemia. Mean anticoagulation score after dialysis was 4.8 +/- 0.7 for the arterial bubble trap, 4.6 +/- 0.8 for the dialyzer and 4.8 +/- 0.7 for the venous bubble trap. Serum citrate after dialysis was 158 +/- 60 micromol/l.

Conclusion: Regional citrate anticoagulation in single-needle dialysis is safe and efficient.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Citrates / therapeutic use*
  • Female
  • Hemodialysis Solutions / chemistry*
  • Hemodialysis Solutions / pharmacology*
  • Hemorrhage
  • Humans
  • Hypocalcemia
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy
  • Male
  • Middle Aged
  • Prospective Studies
  • Renal Dialysis / adverse effects
  • Renal Dialysis / methods*

Substances

  • Anticoagulants
  • Citrates
  • Hemodialysis Solutions
  • trisodium citrate